{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-24-000045","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.638457+00:00","generated_at":"2026-06-03T02:41:55.958413+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515","bullets":["Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).","Net loss $54.7M vs net income $129.1M in Q1 2023; non-GAAP net loss $62.4M.","FDA cleared IND for SGR-3515 (Wee1/Myt1 inhibitor); Phase 1 solid tumors trial expected Q3 2024.","SGR-1505 and SGR-2921 Phase 1 data readouts expected late 2024 or 2025.","Rights to SOS1 inhibitor reverted from BMS after portfolio prioritization."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-24-000045","json":"https://secwatch.observer/filing/0001490978-24-000045.json","markdown":"https://secwatch.observer/filing/0001490978-24-000045.md","text":"https://secwatch.observer/filing/0001490978-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/0001490978-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/sdgr-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:41:55.958413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3808ce7be91beb24ef38cfb7b226f24fc0ee2fb5","claim":"Schrodinger, Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million, net income $(54.7) million. Guidance reaffirmed.","evidence_excerpt":"expressly incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/0001490978-24-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$36.6 million"},{"label":"Net income","value":"$(54.7) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}